Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adocia (ADOCY : OTC)

• Company Description    Adocia SAS is a biotechnology company which is engaged in the development of insulin therapy. The Company develops a BioChaperone platform used for therapeutic protein delivery in regenerative medicine and chronic disease. Adocia SAS is based in Lyon, France. Number of Employees: 77

• Price / Volume Information    Yesterday's Closing Price: $11.80 Daily Weekly Monthly 20 Day Moving Average: 0 shares Shares Outstanding: 18.28 (millions) Market Capitalization: $215.70 (millions) Beta: -0.12 52 Week High: $ 52 Week Low: $ Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -5.03% 12 Week 0.00% -12.90% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 115 Avenue Lacassagne - Lyon,I0 69003 FRA ph: 33-04-72-61-06-10 fax: 33-04-72-36-39-67 plaurent@newcap.fr http://www.adocia.com

• General Corporate Information    Officers Olivier Soula - Chief Executive Officer and Director Gerard Soula - Chairman of the Board and Director Ekaterina Smirnyagina - Director Valerie Moumdjian - Director Mads Dall - Director Peer Information Adocia (CORR.) Adocia (RSPI) Adocia (CGXP) Adocia (BGEN) Adocia (GTBP) Adocia (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00725J102 SIC: 8880 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 18.28 Most Recent Split Date: (:1) Beta: -0.12 Market Capitalization: $215.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 1.08 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 1.07 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -69.03 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - -0.21 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©